Zantac cancer

Popular antacid tablets containing Ranitidine might be carcinogenic. The Ministry of Health and Prevention (MoHAP) has issued a circular to all health facilities and practitioners, informing them about the precautionary suspension of the registration, importation and distribution of all medicines containing ranitidine, while asking patients to continue with their current medication until replacement is found.
Ranitidine is very popular as its brand name in india such as zantac, rantac, aciloc, ranidom rd, r loc etc
If you are from india then you should watch this video for further step regarding this matter.
๐Ÿ‘‡๐Ÿ‘‡๐Ÿ‘‡๐Ÿ‘‡๐Ÿ‘‡๐Ÿ‘‡๐Ÿ‘‡๐Ÿ‘‡๐Ÿ‘‡๐Ÿ‘‡๐Ÿ‘‡๐Ÿ‘‡๐Ÿ‘‡๐Ÿ‘‡๐Ÿ‘‡





Although leading regulators such as the  and the European Medicines Agency (EMA) have not banned the drug, regulators have alerted public to be cautious and consult their doctors. However, many leading drugmakers, including India's Dr Reddy's Laboratories, have stopped sales until there is clarity. The Indian drug regulator and the Indian Medical Association are yet to come up with a warning to public and manufacturers. Swiss drug maker Novartis's generic arm Sandoz has also recalled the drug voluntarily.

An old molecule with most versions off-patent, the global ranitidine market that includes tablets, syrups and injections usually prescribed for intestinal and stomach ulcers, Gastroesophageal Reflux Disease (GERD), esophagitis, Zollinger-Ellison syndrome and others was valued at $412.4 million in 2017. The drug and its variants are expected to grow at a compound annual growth rate (CAGR) of 1.8 per cent to reach $485.4 million by 2026, says a market forecast by Coherent Market Insights.

In India, various drugmakers such as Dr Reddy's, Sun Pharma, Cadila Pharma, GlaxoSmithKline, JB Chemicals and Zydus Cadila sell over 180 products based on ranitidine. The domestic market sales are pegged at around Rs 700-750 crore. Aurobindo Pharma, Granules India, and Strides Shasun are some of companies that got approval to sell this product in the US. "Most generic drugmakers target $5-10 million sales from such old molecules as these steadily contribute to their annual sales," said sources.



The FDA said it has been investigating the carcinogen, called N-nitrosodimethylamine or NDMA, in blood pressure and heart failure medicines since last year and is evaluating whether low levels pose a risk to patients.

“The FDA is not calling for individuals to stop taking ranitidine at this time; however, patients taking prescription ranitidine who wish to discontinue use should talk to their health care professional about other treatment options,” the FDA said in the statement.

Like our article if this is usefull for you and never forgot to follow us.
Please share this article with your relatives and family members and friends thus they also aware about this matter
Thanks

Comments

Popular posts from this blog

Levolin Respule 0.63 Cipla Review || How to Use & What are benefits ?

Is dexorange syrup contains blood

is ranitidine banned in india